1 Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; and.
2 The Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Am J Respir Crit Care Med. 2019 Apr 15;199(8):952-960. doi: 10.1164/rccm.201809-1677CI.
Intravenous fluid therapy is the most common intervention received by acutely ill patients. Historically, saline (0.9% sodium chloride) has been the most frequently administered intravenous fluid, especially in North America. Balanced crystalloid solutions (e.g., lactated Ringer's, Plasma-Lyte) are an increasingly used alternative to saline. Balanced crystalloids have a sodium, potassium, and chloride content closer to that of extracellular fluid and, when given intravenously, have fewer adverse effects on acid-base balance. Preclinical research has demonstrated that saline may cause hyperchloremic metabolic acidosis, inflammation, hypotension, acute kidney injury, and death. Studies of patients and healthy human volunteers suggest that even relatively small volumes of saline may exert physiological effects. Randomized trials in the operating room have demonstrated that using balanced crystalloids rather than saline prevents the development of hyperchloremic metabolic acidosis and may reduce the need for vasopressors. Observational studies among critically ill adults have associated receipt of balanced crystalloids with lower rates of complications, including acute kidney injury and death. Most recently, large randomized trials among critically ill adults have examined whether balanced crystalloids result in less death or severe renal dysfunction than saline. Although some of these trials are still ongoing, a growing body of evidence raises fundamental concerns regarding saline as the primary intravenous crystalloid for critically ill adults and highlights fundamental unanswered questions for future research about fluid therapy in critical illness.
静脉输液治疗是急性病患者最常接受的干预措施。从历史上看,盐水(0.9%氯化钠)是最常使用的静脉输液,尤其是在北美。平衡晶体溶液(如乳酸林格氏液、血浆代用品)是盐水的一种越来越常用的替代物。平衡晶体具有更接近细胞外液的钠、钾和氯含量,静脉给予时对酸碱平衡的不良影响较小。临床前研究表明,盐水可能导致高氯性代谢性酸中毒、炎症、低血压、急性肾损伤和死亡。对患者和健康人类志愿者的研究表明,即使是相对较小体积的盐水也可能产生生理效应。手术室中的随机试验表明,使用平衡晶体溶液而不是盐水可预防高氯性代谢性酸中毒的发生,并可能减少血管加压药的需求。对重症成人的观察性研究表明,使用平衡晶体溶液与较低的并发症发生率相关,包括急性肾损伤和死亡。最近,对重症成人的大型随机试验研究了平衡晶体溶液是否比盐水导致更少的死亡或严重肾功能障碍。尽管其中一些试验仍在进行中,但越来越多的证据引起了人们对将盐水作为重症成人主要静脉晶体液的基本关注,并突出了有关危重病液体治疗的未来研究中尚未回答的基本问题。